Several cytokines, including IL-5, IL-6, IL-8, IL-4, and IL-10, have been identified as potential prognostic factors in NSCLC patients receiving anti-PD-1 treatment in combination with chemotherapy [33]. This evidence concerns the gene IL10 and non-small cell lung carcinoma.